- Previous Close
0.0001 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0000 - Volume
50,560 - Avg. Volume
0 - Market Cap (intraday)
1.096M - Beta (5Y Monthly) -30.13
- PE Ratio (TTM)
∞ - EPS (TTM)
0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. The company supplies natural astaxanthin, a nutrient used as a source of pigment for coloring farmed salmon and trout species. It also supplies ingredients and finished products to the nutraceutical and feed industry. The company also provides research and development services for microbial strain improvement and fermentation process development and scale up from shake flask, to pilot plant, to commercial sized fermentors; and analytical chemistry services for identification and quantization of carotenoids in foods, feeds, and animal tissues, including verification of wild versus farm raised salmonids. The company was formerly known as IGI Biotechnology, Inc. and changed its name to IGENE Biotechnology, Inc. in April 1986. IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland.
www.igene.com18
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: IGNE
View MorePerformance Overview: IGNE
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IGNE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IGNE
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-8.21%
Return on Equity (ttm)
--
Revenue (ttm)
4.8k
Net Income Avi to Common (ttm)
-2.37M
Diluted EPS (ttm)
0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
269.29k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-442.78k